{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:07:25Z","timestamp":1791295645967,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.critrevonc.2016.06.013","type":"journal-article","created":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T14:00:21Z","timestamp":1466949621000},"page":"112-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6695-7994","authenticated-orcid":false,"given":"Aziz","family":"Nazha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.critrevonc.2016.06.013_bib0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2141.2009.07804.x","article-title":"Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients","volume":"146","author":"Alvarez-Larran","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.06.013_bib0010","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response: resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larran","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.06.013_bib0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/bjc.1981.150","article-title":"Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. Leukemia and Hematosarcoma Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.)","volume":"44","year":"1981","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.06.013_bib0020","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia","volume":"123","author":"Anon","year":"1995","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.06.013_bib0025","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.06.013_bib0030","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9464","key":"10.1016\/j.critrevonc.2016.06.013_bib0035","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.critrevonc.2016.06.013_bib0040","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2016.06.013_bib0045","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.1984.2.6.558","article-title":"Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia","volume":"2","author":"Brusamolino","year":"1984","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2016.06.013_bib0050","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood.V77.12.2790.2790","article-title":"Recombinant interferon alpha in the treatment of polycythemia vera","volume":"77","author":"Cacciola","year":"1991","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.06.013_bib0055","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V70.4.1014.1014","article-title":"Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM: CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia","volume":"70","author":"Carlo-Stella","year":"1987","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.06.013_bib0060","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2141.1994.tb08324.x","article-title":"The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera","volume":"87","author":"Castello","year":"1994","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.06.013_bib0065","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.06.013_bib0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2141.1990.tb02531.x","article-title":"Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis","volume":"74","author":"Chott","year":"1990","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.06.013_bib0075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ajh.2830440303","article-title":"Recombinant interferon alpha-2b in the treatment of polycythemia vera","volume":"44","author":"Cimino","year":"1993","journal-title":"Am. J. Hematol."},{"issue":"22","key":"10.1016\/j.critrevonc.2016.06.013_bib0080","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.06.013_bib0085","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.1990.tb02647.x","article-title":"Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon","volume":"75","author":"Dudley","year":"1990","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2016.06.013_bib0090","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.06.013_bib0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2016.06.013_bib0100","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2003-01-0135","article-title":"Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis","volume":"101","author":"Finazzi","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.06.013_bib0105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.2830430419","article-title":"Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa","volume":"43","author":"Finelli","year":"1993","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.06.013_bib0110","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0609.1998.tb01039.x","article-title":"Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera","volume":"60","author":"Foa","year":"1998","journal-title":"Eur. J. Haematol."},{"issue":"24","key":"10.1016\/j.critrevonc.2016.06.013_bib0115","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1182\/blood-2014-05-577635","article-title":"Therapy for myeloproliferative neoplasms: when, which agent, and how?","volume":"124","author":"Geyer","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.06.013_bib0120","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.06.013_bib0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0609.1999.tb01110.x","article-title":"The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera","volume":"62","author":"Heis","year":"1999","journal-title":"Eur. J. Haematol."},{"issue":"7037","key":"10.1016\/j.critrevonc.2016.06.013_bib0130","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2016.06.013_bib0135","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2016.06.013_bib0140","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.critrevonc.2016.06.013_bib0145","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells","volume":"24","author":"Kiladjian","year":"2010","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.06.013_bib0150","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00063030-200115070-00001","article-title":"Development of pegylated interferons for the treatment of chronic hepatitis C","volume":"15","author":"Kozlowski","year":"2001","journal-title":"BioDrugs"},{"issue":"17","key":"10.1016\/j.critrevonc.2016.06.013_bib0155","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2016.06.013_bib0160","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2005-05-1889","article-title":"Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2","volume":"106","author":"Kralovics","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.06.013_bib0165","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.pharmthera.2004.12.002","article-title":"Evolution of the Class 2 cytokines and receptors: and discovery of new friends and relatives","volume":"106","author":"Krause","year":"2005","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2016.06.013_bib0170","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V80.8.1965.1965","article-title":"Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo","volume":"80","author":"Landolfi","year":"1992","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.06.013_bib0175","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.06.013_bib0180","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera: essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.critrevonc.2016.06.013_bib0185","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.06.013_bib0190","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.06.013_bib0195","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/(SICI)1096-8652(199710)56:2<126::AID-AJH10>3.0.CO;2-A","article-title":"Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone","volume":"56","author":"Massaro","year":"1997","journal-title":"Am. J. Hematol."},{"issue":"November (26)","key":"10.1016\/j.critrevonc.2016.06.013_bib0200","article-title":"Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy","author":"Mesa","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.06.013_bib0205","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2141.1995.tb03306.x","article-title":"Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera","volume":"89","author":"Muller","year":"1995","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.06.013_bib0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2141.1994.tb03289.x","article-title":"The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group","volume":"86","author":"Najean","year":"1994","journal-title":"Br. J. Haematol."},{"issue":"24","key":"10.1016\/j.critrevonc.2016.06.013_bib0215","doi-asserted-by":"crossref","first-page":"15011","DOI":"10.1016\/S0021-9258(17)43764-1","article-title":"Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells","volume":"258","author":"Ortaldo","year":"1983","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.06.013_bib0220","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1600-0609.1994.tb00191.x","article-title":"Recombinant alpha 2a interferon and polycythemia vera: clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy","volume":"53","author":"Papineschi","year":"1994","journal-title":"Eur. J. Haematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2016.06.013_bib0225","first-page":"1011","article-title":"Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients","volume":"85","author":"Passamonti","year":"2000","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.06.013_bib0230","first-page":"13","article-title":"Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia","volume":"88","author":"Passamonti","year":"2003","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.critrevonc.2016.06.013_bib0235","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2016.06.013_bib0240","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.06.013_bib0245","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon-like cytokines, and their receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.06.013_bib0250","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.leu.2401045","article-title":"Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971\u20131991)","volume":"12","author":"Petti","year":"1998","journal-title":"Leukemia"},{"issue":"32","key":"10.1016\/j.critrevonc.2016.06.013_bib0255","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.06.013_bib0260","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cncr.11486","article-title":"Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group","volume":"98","author":"Radin","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.06.013_bib0265","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00280-009-0991-z","article-title":"Hydroxyurea and hydroxamic acid derivatives as antitumor drugs","volume":"64","author":"Saban","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"10.1016\/j.critrevonc.2016.06.013_bib0270","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","article-title":"A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life","volume":"106","author":"Samuelsson","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2016.06.013_bib0275","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","article-title":"Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms","volume":"115","author":"Schaub","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2016.06.013_bib0280","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"8607","key":"10.1016\/j.critrevonc.2016.06.013_bib0285","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)92881-4","article-title":"Recombinant interferon-alpha for treatment of polycythaemia vera","volume":"2","author":"Silver","year":"1988","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.06.013_bib0290","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.critrevonc.2016.06.013_bib0295","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2016.06.013_bib0300","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00277-014-2205-y","article-title":"Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options","volume":"93","author":"Stein","year":"2014","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.06.013_bib0305","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2141.1996.00303.x","article-title":"Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data","volume":"92","author":"Taylor","year":"1996","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.06.013_bib0310","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2016.06.013_bib0315","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera: essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.06.013_bib0320","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.06.013_bib0325","first-page":"75","article-title":"Alpha-interferon in polycythemia vera and essential thrombocythemia","volume":"76","author":"Turri","year":"1991","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.critrevonc.2016.06.013_bib0330","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.critrevonc.2016.06.013_bib0335","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2014-07-551929","article-title":"How I treat polycythemia vera","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.06.013_bib0340","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The world health organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2016.06.013_bib0345","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.06.013_bib0350","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind: placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.06.013_bib0355","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T05:48:18Z","timestamp":1656740898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816301469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":71,"alternative-id":["S1040842816301469"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.06.013","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}